Lentinan — разлика између измена
Садржај обрисан Садржај додат
Нова страница: {{run}} {{Drugbox-lat | verifiedrevid = 451110455 | IUPAC_name = β--{<small>D</small>}--glukopiranozil-(1→6)-[β--{<small>D</small>}--glukopiranozil-(1→3)-[… |
(нема разлике)
|
Верзија на датум 22. септембар 2012. у 02:41
 | |
| IUPAC ime | |
|---|---|
β-D-glukopiranozil-(1→6)-[β-D-glukopiranozil-(1→3)-[β-D-glukopiranozil-(1→6)]-β-D-glukopiranozil-(1→3)-β-D-glukopiranozil-(1→3)β-D-glukopiranozil-(1→3)]-β-D-glukopiranoza | |
| Klinički podaci | |
| Drugs.com | Internacionalno ime leka |
| Identifikatori | |
| CAS broj | 37339-90-5  |
| ATC kod | L03AX01 (WHO) |
| PubChem | CID 37723 |
| KEGG | D01695 |
| Sinonimi | (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihidroksi-2-(hidroksimetil)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksioksan-4-il]oksi-3,5-dihidroksi-6-(hidroksimetil)oksan-4-il]oksi-3,5-dihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksi-6-(hidroksimetil)oksan-3,4,5-triol |
| Hemijski podaci | |
| Formula | C42H72O36 |
| Molarna masa | 1152.99948 g/mol |
Lentinan je beta-glucan with a glycosidic β-1,3:β-1,6 linkage.[1] It is an anti-tumor polysaccharide from the shiitake (Lentinula edodes) mushroom.[1] Lentinan is a polysaccharide that has a molecular weight of approximately 500,000 Da. The Japanese pharmaceutical company Ajinomoto developed Lentinan, which is an intravenously administered anti-cancer agent.[1]
Lentinan is one of the host-mediated anti-cancer drugs[2] which has been shown to affect host defense immune systems.[3]
Klinička israživanja na obolelima od raka su ukazala na vezu između lentinana i povišenog stepena perživljavanja, poboljšanog kvaliteta života, i umanjene ponovne pojave kancera.[4][5][6][7][8][9][10][11]
Reference
- ^ а б Cancer Guide Includes many abstracts
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061.
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061.
- ^
Yang P, Liang M, Zhang Y, Shen B. (2008). „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.”. Adv Ther. 25 (8): 787—94. PMID 18670743. doi:10.1007/s12325-008-0079-x. Непознати параметар
|month=игнорисан (помоћ) - ^
Nimura H, Mitsumori N, Takahashi N, (2006). „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]”. Gan to Kagaku Ryoho. 33 (1): 106—9. PMID 16897983. Непознати параметар
|month=игнорисан (помоћ) - ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061.
- ^ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2009). „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer”. Anticancer Res. 29 (7): 2739—45. PMID 19596954. Непознати параметар
|month=игнорисан (помоћ) - ^ Hazama S, Watanabe S, Ohashi M; et al. (2009). „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer”. Anticancer Res. 29 (7): 2611—7. PMID 19596936. Непознати параметар
|month=игнорисан (помоћ) - ^ Kataoka H, Shimura T, Mizoshita T; et al. (2009). „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life”. Hepatogastroenterology. 56 (90): 547—50. PMID 19579640.
- ^ Isoda N, Eguchi Y, Nukaya H; et al. (2009). „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma”. Hepatogastroenterology. 56 (90): 437—41. PMID 19579616.
- ^ Shimizu K, Watanabe S, Watanabe S; et al. (2009). „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer”. Hepatogastroenterology. 56 (89): 240—4. PMID 19453066.
Literatura
- Chihara, G. et al. ”Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom)”, Cancer Research (1970),30(11):2776-2781.
- Ina, K. et al. “Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy”, World Journal of Clinical Oncology (2011),2(10):339-343.
Vidi još
Spoljašnje veze
- Lentinan effects (antitumor and others)